Filing Flows › BioNexus Gene Lab (BGLC) › Q1 2026
BioNexus Gene Lab (BGLC) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
BioNexus Gene Lab (BGLC) reported revenue of $23K for the first quarter 2026 (Q1 2026), -99% from a year earlier and -95% from the quarter before.
BioNexus Gene Lab, Q1 2026: revenue $23K (-99% year over year), net loss $544K, operating cash flow −$148K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $23K | -95% | -99% |
| Operating profit | −$540K | — | — |
| Net earnings | −$544K | — | — |
| Operating cash flow | −$148K | -115% | — |
What changed
Revenue was $23K in Q1 2026, down 99% year over year and down 95% from the previous quarter.
Operating costs exceeded revenue by $540K, an operating margin of -2366.2%. The fastest-growing cost line was Other operating costs (+742%). The quarter ended with a net loss of $544K, narrower than the previous quarter's $1.0M loss.
Operating cash flow was −$148K. Non-cash charges added back $28K of depreciation. Working capital and other items added $368K. Capital expenditures of $0K exceeded it, leaving free cash flow of −$148K.
Questions
What was BioNexus Gene Lab's revenue in the first quarter 2026?
BioNexus Gene Lab (BGLC) reported revenue of $23K for the first quarter 2026 (Q1 2026), -99% from a year earlier and -95% from the quarter before.
Source: BioNexus Gene Lab 10-Q on SEC EDGAR.